Clinical Trials
Sponsor:
Sponsor Study ID:
Study Title:
A Phase 2, Open Label, Multi Center Study of PDS0101 (R DOTAP [Versamune®] + HPVmix) and Pembrolizumab (KEYTRUDA®) Combination Immunotherapy in Subjects with Recurrent and/or Metastatic Head and Neck Cancer and High Risk Human Papillomavirus 16 (HPV16) Infection
NCT Number:
NCT04260126
Phase:
II
Protocol Type:
Treatment
Age Group:
Adults
Disease Sites:
Lip, Oral Cavity and Pharynx
Study Objectives:
VERSATILE-002 is a Phase 2, open-label, multicenter study of the efficacy and safety of PDS0101 administered in combination with pembrolizumab in the first line treatment of adults with HPV16 and PD-L1 positive recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).
Study Documents
(MUSC NetID required for document access)